| Primary information |
|---|
| ID | antitb_1649, |
| Name | 19319854 |
| N-Terminal modification | Tuftsin peptide conjugate compound |
| C-Terminal Modification | SEFAYGSFVRTVSLPV |
| Chemical Modification | INH is conjugated |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from 16-kDa protein of M. tuberculosis and tuftsin-derived peptides |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv ATCC 27294 |
| Cell Line | MIC = 2.54 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Cell wall biosynthesis inhibition |
| Other activities | NA |
| PMID | Peptide + INH(0.24 ug/ml) |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1650, |
| Name | 19319854 |
| N-Terminal modification | Tuftsin peptide conjugate compound |
| C-Terminal Modification | SEFAYGSFVRTVSLPV |
| Chemical Modification | INH is conjugated |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Cyclic |
| Nature | 16 |
| Source | L |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from 16-kDa protein of M. tuberculosis and tuftsin-derived peptides |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv ATCC 27294 |
| Cell Line | MIC = 2.26μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2009 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Cell wall biosynthesis inhibition |
| Other activities | NA |
| PMID | Peptide + INH(0.24 ug/ml) |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |